JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25 August 2023 and which was later reported by the researchers to have higher transmissibility and immune escape ability, has now been designated a variant of interest (VOIs) by WHO.

In the last few weeks, JN.1 cases have been reported in many countries. Its prevalence is rapidly increasing globally. In view of rapidly increasing spread, WHO has classified JN.1 as a separate variant of interest (VOI).

As per initial risk evaluation by WHO, the additional public health risk posed by JN.1 sub-variant is low at the global level.

Notwithstanding higher infection rate and possibility of immunity evasion, current evidence does not suggest that the disease severity could be higher compared to other circulating variants.

***

References:

  1. WHO.  Tracking SARS-CoV-2 variants – Currently circulating variants of interest (VOIs) (as of 18 December 2023). Available at https://www.who.int/activities/tracking-SARS-CoV-2-variants
  2. WHO. JN.1 Initial Risk Evaluation 18 December 2023. Available at https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3 

***

Latest

Daraxonrasib Approved for Pancreatic Cancer

Daraxonrasib (Rasonque by Revolution Medicines, Inc.), an inhibitor of...

Glacial Collapse Led to Seismic Event in Nepal 

The magnitude 5.2 seismic event recorded near the border...

Significance of Nancy Grace Roman Space Telescope

Nancy Grace Roman Space Telescope (commonly referred to as...

NASA Invites ISRO to Join Moon Base Programme

NASA has invited ISRO (Indian Space Research Organisation) to...

2026 Total Solar Eclipse

On 12 August 2026, a total solar eclipse was...

AI Designs Complete Functional Genomes

The genome language model Evo 2 has designed novel...

Newsletter

Don't miss

Self-amplifying mRNAs (saRNAs): The Next Generation RNA Platform for Vaccines 

Unlike conventional mRNA vaccines which encodes only for the...

Probiotics Not Effective Enough in Treating ‘Stomach Flu’ in children

Twin studies show that expensive and popular probiotics may...

Biological Barriers of Reproduction from Same-Sex Mammals Overcome

Study shows for the first time healthy mouse offspring...

Drug Trials for COVID-19 Begins in the UK and USA

Clinical Trials to evaluate effectiveness of anti-malarial drug, hydroxychloroquine...

Anxiety Relief Through Probiotic and Non-Probiotic Diet Adjustments

A systematic review provides comprehensive evidence that regulating microbiota...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Daraxonrasib Approved for Pancreatic Cancer

Daraxonrasib (Rasonque by Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family has been approved for the treatment of adults with metastatic pancreatic...

Glacial Collapse Led to Seismic Event in Nepal 

The magnitude 5.2 seismic event recorded near the border between Nepal and China on 26 August 2026 at 8:37 AM local time (02:52:10 UTC) has...

Significance of Nancy Grace Roman Space Telescope

Nancy Grace Roman Space Telescope (commonly referred to as Roman Telescope) is set to be launched into space on 30 August 2026. It will...

LEAVE A REPLY

Please enter your comment!
Please enter your name here